IDH1 and neoplasm: Based on these mechanistic insights and strong correlation of mIDH1 with the non-T cell-inflamed phenotype across tumor types (Supplemental Figure S1), we hypothesized that IDH1 inhibition combined with ICI may be an effective treatment strategy for patients with mIDH1 tumors.